Menu
Search
|

Menu

Close
X

Amgen Inc AMGN.OQ (NASDAQ Stock Exchange Global Select Market)

194.91 USD
-- (--)
As of Nov 19
chart
Previous Close 194.91
Open --
Volume --
3m Avg Volume 1,128,912
Today’s High --
Today’s Low --
52 Week High 210.18
52 Week Low 163.31
Shares Outstanding (mil) 637.22
Market Capitalization (mil) 122,059.30
Forward P/E 15.80
Dividend (Yield %) 1.32 ( 2.76 )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.33 Mean rating from 24 analysts

KEY STATS

Revenue (mm, USD)
FY18
17,517
FY17
22,849
FY16
22,991
FY15
21,662
EPS (USD)
FY18
9.594
FY17
10.999
FY16
10.260
FY15
9.060
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
15.80
29.34
Price to Sales (TTM)
vs sector
5.23
20.58
Price to Book (MRQ)
vs sector
8.55
4.23
Price to Cash Flow (TTM)
vs sector
11.96
21.19
Total Debt to Equity (MRQ)
vs sector
239.93
13.84
LT Debt to Equity (MRQ)
vs sector
204.54
9.93
Return on Investment (TTM)
vs sector
13.07
13.58
Return on Equity (TTM)
vs sector
35.65
15.11

EXECUTIVE LEADERSHIP

Robert Bradway
Chairman of the Board, President, Chief Executive Officer, Since 2013
Salary: $1,555,960.00
Bonus: --
David Meline
Executive Vice President, Chief Financial Officer, Since 2014
Salary: $970,769.00
Bonus: --
Murdo Gordon
Executive Vice President of Global Commercial Operations, Since 2018
Salary: --
Bonus: --
David Reese
Executive Vice President - Research and Development, Since 2018
Salary: --
Bonus: --
Esteban Santos
Executive Vice President, Operations, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

1 Amgen Center Dr
THOUSAND OAKS   CA   91320-1730

Phone: +1805.4471000

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.

SPONSORED STORIES